THCbiz

Advertisement

Mon01212019

      Cannabis Industry B2B Directory: Featured Businesses
Back You are here: Home News Company News Nuvilex's Medical Marijuana Subsidiary Poised for Growth in the New Year

Nuvilex's Medical Marijuana Subsidiary Poised for Growth in the New Year


NEW YORK, NY — Nuvilex, Inc. (otcqb:NVLX) will be starting 2014 off with a flurry of activity inside its wholly owned subsidiary, Medical Marijuana Sciences, Inc. (MMS). After naming Dr. Mark L. Rabe, a leading figure in the medical marijuana industry, as Chairman of the Scientific Advisory Board (SAB) for MMS last month, the company announced this week that Dr. Rabe has developed a Charter and established a list of goals and objectives for the subsidiary.

Nuvilex, an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, created its medical marijuana subsidiary to enhance its own research in an effort to address difficult to treat cancers using the drug. Entering an election year, 2014 is sure to be busy in the sector which only adds to the buzz surrounding MMS and other marijuana stocks as they continue to grow and begin research.

In the company's announcement last week, Dr. Rabe's Charter spelled out the Scientific Advisory Board's mission. First, MMS's work will be to develop disease treatments that utilize constituents of Cannabis through the use of Nuvilex's proprietary Cell-in-a-Box(TM) cellulose-based live-cell encapsulation technology. According to the company, the initial emphasis will be placed on the development of treatments for brain and pancreatic cancers, two of the deadliest and most difficult-to-treat forms of the disease.

Additionally, the SAB will establish Medical Marijuana Sciences as an industry leader in the development of Cannabis-based disease treatments. In the Charter, Dr. Rabe also outlined a number of goals and objectives of the SAB in its efforts to advise Medical Marijuana Sciences as a whole.

Those goals and objectives include: providing an objective and diversified perspective on the science and technology related to the use of Cannabis for treatments of diseases; assisting in drug development and clinical research; validating the science and technology; assisting in developing a pipeline of products; establishing critical connections with academic research; and evaluating new technologies and intellectual properties and assess the market potential of each as they relate to the Charter of Medical Marijuana Sciences.

Nuvilex, through its subsidiary, has moved headlong into the medical marijuana arena, and with Dr. Rabe leading the way, 2014 should see MMS make great strides toward beginning its mission. Nuvilex also announced Dr. Rabe has begun to recruit individuals worldwide with the credentials it will take to accomplish the Charter he's laid out, and to become members of the SAB of MMS.

About Stock Market Media Group

Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Reports, Interviews and Feature Articles. For more information and to read disclaimers and disclosures: www.stockmarketmediagroup.com

Safe Harbor Statement 

This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.

SOURCE: Nuvilex, Inc.


Advertisement
Advertisement